Title

Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004
Single-blind Randomized Controlled Phase II/III Study to Investigate the Immunogenicity and Safety of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived) in Comparison to a Licensed Egg-derived Influenza Vaccine for Season 2003/2004
  • Phase

    Phase 2/Phase 3
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Study Participants

    None
The objectives of the study are to assess the immunogenicity and safety of the inactivated influenza vaccine (whole virion, Vero cell-derived) at Day 21 and Day 180 after vaccination.
Study Started
Dec 31
2003
Study Completion
Jul 31
2004
Last Update
Oct 09
2015
Estimate

Biological Vero Cell-derived Influenza Vaccine

Biological Egg-derived Influenza Vaccine

Criteria

Inclusion Criteria:

Male and female subjects will be eligible for participation in this study if they:

are >= 18 and <= 60 years old (for Stratum A only);
are > 60 years old (for Stratum B only);
are in a physical condition such that the physician would have no reservations vaccinating with an influenza vaccine outside the scope of a clinical trial;
will reliably keep a daily record of symptoms;
understand the nature of the study, agree to its provisions, and give written informed consent;
if female and capable of bearing children - show a negative pregnancy test result at study entry and agree to employ adequate birth control measures for the duration of the study.

Exclusion Criteria:

Male and female subjects will be excluded from participation in this study if they:

have received any influenza vaccine for the 2002/2003 season and/or for the 2003/2004 season;
suffer from any kind of immunodeficiency;
suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence immunological functions;
have a history of inflammatory or degenerative neurological disease (e.g. Guillain Barré, multiple sclerosis);
have received a blood transfusion or immunoglobulins within one month of study entry;
have a history of any vaccine-related contraindicating event (e.g. anaphylaxis);
have a rash or dermatological condition which may interfere with injection site reaction rating;
have a known or suspected problem with drug or alcohol abuse;
are unable to lead an independent life either physically or mentally;
had administration of an investigational drug within six weeks prior to the study start;
are concurrently participating in a clinical trial;
are pregnant or lactating.
No Results Posted